



DT17REG/PCT/PTO 07 FEB 2003

TJK/209

IN THE UNITED STATES PATENT AND TRADEMARKS OFFICE

In re Application of: Kaveri

Serial No.: 10/031,938

Filed: 01/22/2002

CATALYTIC ANTI-
FACTOR VIII
ANTIBODIES

Group Art Unit:

TRANSMITTAL LETTER

Commissioner of Patent and Trademarks
Washington, D.C. 20231

Sir:

RECEIVED

APR 24 2003

TECH CENTER 1600/2900

Please find enclosed the following in the above referenced patent application:

1. Transmittal Letter (in duplicate);
2. Amendment of Sequence Listing;
3. Paper copy of amended Sequence Listing;
4. Copy of Second Preliminary Amendment previously filed;
5. Two (2) 3.5 computer floppy disks containing the Sequence Listing in American Standard Code for Information Interchange (ASCII) text;
6. Duplicate Notice of Notification of Defective Response; and
7. Postcard.

Please acknowledge receipt of the above by returning the enclosed stamped, self-addressed receipt postcard.

Please charge any additional fees which include any extension fees due to Deposit Account No. 23-2126. A duplicate of this transmittal is enclosed.

Respectfully submitted,

Date: Mar 31, 2003
Wildman, Harrold, Allen & Dixon
225 West Wacker Drive
Chicago, IL 60606
Ph. (312) 201-2000
Fax (312) 201-2555

By: Timothy J. Kofer, Reg. No. 35,567



Kaveri et al. 10/031,938

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Kaveri et al.

Serial No.: 10/031,938

Filed: January 22, 2002

CATALYTIC ANTI-FACTOR VIII ALLO-
ANTIBODIES

Attorney Docket: TJK/209

Group Art Unit:

Examiner:

TECH CENTER 1600/2900

APR 24 2003

RECEIVED

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with
the U.S. Postal Service as first class mail in an envelope addressed
to: Assistant Commissioner for Patents, Washington, D.C. 20231,
on Jan 31, 2003.

Timothy J. Keefer

Attorney for Applicants

Reg. No. 35567

Date of Signature: Jan 31, 2003

Assistant Commissioner for Patents

Washington, D.C. 20231

AMENDMENT OF SEQUENCE LISTING

Please cancel the sequence listing currently on file and replace it with attached sequence
listing. Substitute sheets containing the amended sequence listing are enclosed per 37 CFR §
1.825(a). The sequence listing has been amended to conform to the requirements of 37 CFR §§
1.821-1.823, in response to the Notice Of Defective Response mailed on December 31, 2002.
The substitute sheets contain no new matter. A diskette containing a copy of the amended

Kaveri et al. 10/031,938
sequence listing is enclosed per 37 CFR 1.825(b). the sequence listing on the diskette is the same as the substitute paper copy submitted with the amendment.

Applicant notes that on previous attempts to submit a copy of the sequence listing on a computer readable medium, the medium has become corrupted, thereby rendering the sequence listing unreadable. Applicant respectfully submits that he should not be penalized for untimely submission of the sequence listing when the media is corrupted during transport, and that steps will be taken to hand-carry a computer-readable copy of the sequence listing into the USPTO if the diskettes attached hereto become corrupted.

Respectfully submitted,

Timothy J. Keefer
Attorney for Applicants
Reg. No. 35567

Dated: Jan 31, 2003

WILDMAN, HARROLD, ALLEN & DIXON
225 West Wacker Drive
Chicago, Illinois 60606-1229
Telephone: (312) 201-2834
Facsimile: (312) 201-2327
e-mail: keefer@wildmanharrold.com